Lumakras (sotorasib)

LumakrasTM (sotorasib) is a drug used to treat certain adults with non-small cell lung cancer (NSCLC) that has:1

  • Spread to other parts of the body (metastatic) or is locally advanced (has progressed within the lung region), and
  • A KRAS G12C genetic mutation, and
  • Been treated with least 1 prior treatment

The U.S. Food and Drug Administration (FDA) also approved 2 companion diagnostics for Lumakras. A companion diagnostic can help determine which people are right for therapy based on tumor features. The approved companion diagnostics look for the KRAS G12C mutation. They include:1,2

  • Guardant360® CDx, which uses a plasma specimen
  • QIAGEN therascreen® KRAS RGQ PCR kit, which uses tumor tissue and is used if no mutation is found in the plasma sample

The FDA granted Lumakras accelerated approval. The FDA may give accelerated approval to new drugs that treat a serious health condition with few or no other treatments and have promising results. This means drugs like Lumakras can be sold sooner.1

NSCLC makes up about 80 to 85 percent of all lung cancers. About 13 percent of people with NSCLC have a KRAS G12C genetic mutation. NSCLCs with this mutation are usually resistant to other drugs used to treat lung cancer.3

What are the ingredients in Lumakras?

The active ingredient in Lumakras is sotorasib.1-4

How does Lumakras work?

Lumakras is a type of drug known as a RAS GTPase family inhibitor. It attaches to the KRAS G12C protein found on cancer cells with the KRAS G12C mutation. By attaching to the protein, Lumakras prevents the cancer cells from growing.3

What are the possible side effects of Lumakras?

The most common side effects of Lumakras include:1,4

  • Nausea
  • Diarrhea
  • Bone or muscle pain
  • Tiredness
  • Liver problems
  • Cough
  • Changes in liver function tests
  • Changes in blood tests

Lumakras may also cause serious side effects, including:4

  • Liver problems
  • Lung or breathing problems

Tell your doctor right away if you have any new or worsening signs of serious side effects, including:4

  • Yellowing of the skin or eyes
  • Nausea
  • Vomiting
  • Dark urine or light-colored stools
  • Appetite loss
  • Stomach pain
  • Tiredness
  • Weakness
  • Bruising or bleeding
  • Shortness of breath
  • Cough
  • Fever

These are not all the possible side effects of Lumakras. Talk to your doctor about what to expect or if you experience any changes that concern you during treatment with Lumakras.

Things to know about Lumakras

Your doctor should monitor your liver function before and during treatment with Lumakras.4

Before taking Lumakras, tell your doctor if you:4

  • Have liver problems
  • Have lung or breathing problems other than lung cancer
  • Take antacid medicines, including proton pump inhibitor (PPI) drugs or H2 blockers

It is not known if Lumakras can cause harm to an unborn baby. Tell your doctor if you are pregnant, breastfeeding, or planning to become pregnant or breastfeed. People should not breastfeed during treatment with Lumakras and for some time after the last dose. Talk to your doctor about your options for breastfeeding while taking Lumakras.4

Before beginning treatment for lung cancer, tell your doctor about all your health conditions and any other drugs, vitamins, or supplements you are taking. This includes over-the-counter drugs.

For more information, read the full prescribing information of Lumakras.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

Written by: Karen Berger | Last reviewed: June 2021